コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 c, and calendar-year-specific rates from the Surveillance, Epidemiology and End Results Program.
2 67 patients with CLL in the population-based Surveillance, Epidemiology and End Results Program.
3 d the general population using data from the Surveillance, Epidemiology and End Results Program.
4 ulated using the National Cancer Institute's Surveillance, Epidemiology, and End Results Program.
5 reported by the National Cancer Institute's Surveillance, Epidemiology, and End Results program.
6 the California Cancer Registry, part of the Surveillance, Epidemiology, and End Results Program.
7 lity database, Nordic Cancer Registries, and Surveillance, Epidemiology, and End Results Program.
8 and relative survival was projected from the Surveillance, Epidemiology, and End Results Program.
9 (age 15 to 39 years) identified through the Surveillance, Epidemiology, and End Results Program.
10 ients were derived from the population-based Surveillance, Epidemiology, and End Results program.
11 GUS than in the white population of the Iowa Surveillance, Epidemiology, and End Results Program.
12 rates and life table data obtained from the Surveillance, Epidemiology, and End Results Program.
13 Patient cases were sampled from within the Surveillance, Epidemiology, and End Results program.
14 egistries of the National Cancer Institute's Surveillance, Epidemiology, and End Results program.
15 the literature and mortality rates from the Surveillance, Epidemiology, and End Results Program.
16 mpared with the white population of the Iowa Surveillance, Epidemiology, and End Results program.
17 cancer registry data for 1973-1994 from the Surveillance, Epidemiology, and End Results program.
18 o 2008, using population-based data from the Surveillance, Epidemiology, and End Results program.
19 19 data from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program.
20 egistries of the National Cancer Institute's Surveillance, Epidemiology, and End Results Program.
21 Data were obtained from the Surveillance, Epidemiology, and End Results program.
22 asive breast cancer incidence rates from the Surveillance, Epidemiology, and End Results program.
23 age-specific incidence rate patterns in the Surveillance, Epidemiology, and End-Results program.
24 e population-based National Cancer Institute Surveillance, Epidemiology, and End-Results program.
27 Data were obtained from the Surveillance, Epidemiology, and End Results program (197
28 obtained from the National Cancer Institute Surveillance, Epidemiology, and End Results program (197
29 sing nationally representative data from the Surveillance, Epidemiology, and End Results program, 197
30 nonseminoma reported to the population-based Surveillance, Epidemiology, and End Results program (198
31 nonseminoma reported to the population-based Surveillance, Epidemiology, and End Results program (198
32 sing nationally representative data from the Surveillance, Epidemiology, and End Results program, 199
33 Data from the Surveillance, Epidemiology, and End Results program (200
34 tified by race and ethnicity and nSES, using Surveillance Epidemiology and End Results Program 2000-2
35 ed through linkage with pathology databases; Surveillance, Epidemiology, and End Results programs; an
36 unction and hazard ratio results, along with Surveillance, Epidemiology, and End Results program and
37 the U.S. cancer population, provided by the Surveillance, Epidemiology, and End Results Program and
39 ho were listed in the linked database of the Surveillance, Epidemiology, and End Results program and
40 sed 1973-2000 data from the population-based Surveillance, Epidemiology, and End Results Program and
42 ence data from the National Cancer Institute Surveillance, Epidemiology, and End Results program and
43 ed in 1 of the 10 study areas covered by the Surveillance, Epidemiology, and End Results Program, and
44 Data were obtained from the Surveillance, Epidemiology, and End Results Program, and
45 ence rate from the National Cancer Institute-Surveillance, Epidemiology, and End Results Program canc
46 e identified cancer cases via linkage to the Surveillance, Epidemiology, and End Results Program canc
47 cer cases (n = 262) were identified from the Surveillance, Epidemiology, and End Results Program canc
48 NG, AND PARTICIPANTS: This cohort study used Surveillance, Epidemiology, and End Results program canc
49 ta from 9 population-based registries of the Surveillance, Epidemiology, and End Results program coll
50 titute's Connecticut Historical Database and Surveillance, Epidemiology, and End Results program coll
52 Using Surveillance, Epidemiology, and End Results Program Data
53 han that reported in the general population (Surveillance, Epidemiology, and End Results Program data
54 n interrupted time-series analysis using the surveillance, epidemiology, and end results program data
55 ence projection modeling using data from the Surveillance, Epidemiology, and End Results Program data
56 nt data from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program data
57 rt study used population-based data from the Surveillance, Epidemiology, and End Results Program data
58 on Registry, the National Cancer Institute's Surveillance, Epidemiology, and End Results Program data
59 etrospective cohort study used data from the Surveillance, Epidemiology, and End Results Program data
60 lation-based cohort study used data from the Surveillance, Epidemiology, and End Results Program data
61 on-based cohort study obtained data from the Surveillance, Epidemiology, and End Results program data
62 From the Surveillance, Epidemiology, and End Results Program data
63 ined data from the National Cancer Institute Surveillance, Epidemiology, and End Results Program for
64 sus and from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program for
65 stries in the US National Cancer Institute's Surveillance, Epidemiology, and End Results Program for
66 ts with primary colon cancer reported to the Surveillance, Epidemiology and End Results Program from
67 nalysis obtained OPC incidence data from the Surveillance, Epidemiology, and End Results program from
68 e and cancer stage and grade observed in the Surveillance, Epidemiology, and End Results program in 2
69 mesothelioma incidence data released by the Surveillance, Epidemiology, and End Results Program in A
70 om population-based cancer registries in the Surveillance, Epidemiology, and End Results Program in t
71 Data sources included the Surveillance, Epidemiology, and End Results Program, Nat
72 Database; Nationwide Readmissions Database; Surveillance, Epidemiology, and End Results program; Nat
73 ellness Survey; Nationwide Inpatient Sample; Surveillance, Epidemiology, and End Results Program; Nat
74 y used data from National Cancer Institute's Surveillance, Epidemiology and End Results Program of 18
76 ive study of the National Cancer Institute's Surveillance, Epidemiology, and End Results program of M
77 trospective analysis that used data from the Surveillance, Epidemiology, and End Results program of t
78 e US cancer population were derived from the Surveillance, Epidemiology, and End Results Program of t
79 ancer incidence rates based on data from the Surveillance, Epidemiology, and End Results Program of t
80 the nine population-based registries of the Surveillance, Epidemiology, and End Results Program of t
81 stracted from 83,686 cases registered in the Surveillance, Epidemiology, and End Results Program of w
82 nt data from the National Cancer Institute's Surveillance, Epidemiology, and End Results program on i
83 linkage with a state cancer registry or the Surveillance, Epidemiology, and End Results program, or
84 fied by linkage to a pathology database, the Surveillance, Epidemiology, and End Results program, or
85 ces in cutaneous melanoma staging within the Surveillance, Epidemiology, and End Results Program regi
86 en (8387 MR examinations) linked to regional Surveillance, Epidemiology, and End Results program regi
87 Data from nine Surveillance, Epidemiology, and End Results program regi
88 ervational cohort study using data from 5 US Surveillance, Epidemiology, and End Results Program regi
89 The National Cancer Institute's Surveillance, Epidemiology, and End Results Program rele
90 he National Center for Health Statistics and Surveillance Epidemiology and End Results program, respe
91 US Surveillance, Epidemiology, and End Results Program (SEE
92 th 95% confidence intervals (CIs), using the Surveillance, Epidemiology, and End Results Program (SEE
93 ectal SRCC in a large patient group from the Surveillance, Epidemiology, and End Results program (SEE
94 (n = 204) and 9 US cancer registries of the Surveillance, Epidemiology, and End Results program (SEE
95 anoma, personal history of other cancer, and Surveillance, Epidemiology, and End Results Program (SEE
96 CP*Trends is a widely used Surveillance, Epidemiology, and End Results Program (SEE
97 ho were diagnosed from 1975 to 2017 from the Surveillance, Epidemiology, and End Results Program (SEE
98 e, a hospital-based cancer registry, and the Surveillance, Epidemiology, and End Results Program (SEE
99 tracted from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program (SEE
100 By using Surveillance, Epidemiology, and End-Results program (SEE
101 NM Classification of Malignant Tumors or the Surveillance, Epidemiology, and End Results Program [SEE
102 ed with age-adjusted cancer incidence in the Surveillance, Epidemiology and End Results Program (SEER
103 agnosed in 2011 through 2012, accrued from 5 Surveillance, Epidemiology and End Results Program sites
104 were the Breast Cancer Prevention Trial, the Surveillance, Epidemiology, and End-Results program, tim
107 pulation-based cancer registry data from the Surveillance, Epidemiology, and End Results Program to M
109 Incidence data (1973-1992) from the Surveillance, Epidemiology, and End Results Program were
110 ific delay-adjusted incidence rates from the Surveillance, Epidemiology, and End Results Program were
111 and incidence-based mortality data from the Surveillance, Epidemiology, and End Results program were
112 on data from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program, whi
113 from 2000 to 2018 included data from the US Surveillance, Epidemiology, and End Results Program, whi
114 nuary 1, 1973, and December 31, 1996, in the Surveillance, Epidemiology, and End Results Program who